Interleukin-16 as a marker of Sézary syndrome onset and stage

Journal of Clinical Immunology

Volumn 31, Issue 1, 2011, Pages 39-50

  Richmond, Jillian ^a   Tuzova, Marina ^a   Parks, Ashley ^a   Adams, Natalie ^b   Martin, Elizabeth ^b   Tawa, Marianne ^b   Morrison, Lynne ^c   Chaney, Keri ^b   Kupper, Thomas S ^b   Curiel Lewandrowski, Clara ^c   Cruikshank, William ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c ARIZONA STATE UNIVERSITY   (United States)

Author keywords

caspase 3; CD26; Cutaneous T cell lymphoma; interleukin 16; malignant T cells; S zary syndrome

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; INTERLEUKIN 15; INTERLEUKIN 16;

ADULT; AGED; AMINO TERMINAL SEQUENCE; ARTICLE; CANCER STAGING; CARBOXY TERMINAL SEQUENCE; CELL COUNT; CELL CYCLE REGULATION; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL ARTICLE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; FLOW CYTOMETRY; GENE TRANSLOCATION; HUMAN; IMMUNOPRECIPITATION; MALE; MEMBRANE PERMEABILITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DOMAIN; PROTEIN LOCALIZATION; SEZARY SYNDROME; UPREGULATION;

AGED; DIPEPTIDYL PEPTIDASE 4; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMANS; INTERLEUKIN-16; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; SEVERITY OF ILLNESS INDEX; SEZARY SYNDROME; SKIN NEOPLASMS;

EID: 79953906721     PISSN: 02719142     EISSN: 15732592     Source Type: Journal    
DOI: 10.1007/s10875-010-9464-8     Document Type: Article

References (49)

1. Bradford PT, Devesa SS, Anderson WF, Toro JR. Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases. Blood. 2009;113:5064-73.
2. Girardi M, Edelson RL. Cutaneous T-cell lymphoma: pathogenesis and treatment. Oncology (Williston Park). 2000;14:1061-76.
3. Criscione VD, Weinstock MA. Incidence of cutaneous T-cell lymphoma in the United States, 1973-2002. Arch Dermatol. 2007;143:854-9.
4. Van Doorn R, Van Kester MS, Dijkman R, Vermeer MH, Mulder AA, Szuhai K, et al. Oncogenomic analysis of mycosis fungoides reveals major differences with Sezary syndrome. Blood. 2009;113:127-36.
5. Thangavelu M, Finn WG, Yelavarthi KK, Roenigk Jr HH, Samuelson E, Peterson L, et al. Recurring structural chromosome abnormalities in peripheral blood lymphocytes of patients with mycosis fungoides/Sezary syndrome. Blood. 1997;89:3371-7.
6. Dippel E, Klemke CD, Goerdt S. Current status of cutaneous T-cell lymphoma: molecular diagnosis, pathogenesis, therapy and future directions. Onkologie. 2003;26:477-83. (Pubitemid 37409894)
7. Willemze R, Jaffe ES, Burg G, Cerroni L, Berti E, Swerdlow SH, et al. WHO-EORTC classification for cutaneous lymphomas. Blood. 2005;105:3768-85. (Pubitemid 40656118)
8. Campbell JJ, Clark RA, Watanabe R, Kupper TS. Sezary syndrome and MF arise from distinct Tcell subsets: a biologic rationale for their distinct clinical behaviors. Blood. 2010;116:767-71.
9. Lonsdorf AS, Hwang ST, Enk AH. Chemokine receptors in T-cell-mediated diseases of the skin. J Invest Dermatol. 2009;129:2552-66.
10. Girardi M, Heald PW, Wilson LD. The pathogenesis of mycosis fungoides. N Engl J Med. 2004;350:1978-88. (Pubitemid 38580201)
11. Girardi M, Heald PW. Cutaneous T-cell lymphoma and cutaneous graft-versus-host disease. Two indications for photopheresis in dermatology. Dermatol Clin. 2000;18:417-23. viii.
12. Sokolowska-Wojdylo M, Wenzel J, Gaffal E, Lenz J, Speuser P, Erdmann S, et al. Circulating clonal CLA(+) and CD4(+) T cells in Sezary syndrome express the skin-homing chemokine receptors CCR4 and CCR10 as well as the lymph node-homing chemokine receptor CCR7. Br J Dermatol. 2005;152:258-64. (Pubitemid 40343595)
13. Sokolowska-Wojdylo M, Wenzel J, Gaffal E, Steitz J, Roszkiewicz J, Bieber T, et al. Absence of CD26 expression on skin-homing CLA+ CD4+ T lymphocytes in peripheral blood is a highly sensitive marker for early diagnosis and therapeuticmonitoring of patientswith Sezary syndrome. Clin Exp Dermatol. 2005;30:702-6. (Pubitemid 41499832)
14. Kelemen K, Guitart J, Kuzel TM, Goolsby CL, Peterson LC. The usefulness of CD26 in flow cytometric analysis of peripheral blood in Sezary syndrome. Am J Clin Pathol. 2008;129:146-56. (Pubitemid 352038603)
15. Wood GS. Lymphocyte activation in cutaneous T-cell lymphoma. J Invest Dermatol. 1995;105:105S-9.
16. Murphy M, Fullen D, Carlson JA. Low CD7 expression in benign and malignant cutaneous lymphocytic infiltrates: experience with an antibody reactive with paraffin-embedded tissue. Am J Dermatopathol. 2002;24:6-16. (Pubitemid 34121780)
17. Erber WN, Mason DY. Expression of the interleukin-2 receptor (Tac antigen/CD25) in hematologic neoplasms. Am J Clin Pathol. 1988;89:645-8.
18. Dalloul A, Laroche L, Bagot M, Mossalayi MD, Fourcade C, Thacker DJ, et al. Interleukin-7 is a growth factor for Sezary lymphoma cells. J Clin Invest. 1992;90:1054-60.
19. Foss FM, Koc Y, Stetler-Stevenson MA, Nguyen DT, O'Brien MC, Turner R, et al. Costimulation of cutaneous T-cell lymphoma cells by interleukin-7 and interleukin-2: potential autocrine or paracrine effectors in the Sezary syndrome. J Clin Oncol. 1994;12:326-35.
20. Zhang Q, Nowak I, Vonderheid EC, Rook AH, Kadin ME, Nowell PC, et al. Activation of Jak/STAT proteins involved in signal transduction pathway mediated by receptor for interleukin 2 in malignant T lymphocytes derived from cutaneous anaplastic large T-cell lymphoma and Sezary syndrome. Proc Natl Acad Sci USA. 1996;93:9148-53.
21. Dobbeling U, Dummer R, Laine E, Potoczna N, Qin JZ, Burg G. Interleukin-15 is an autocrine/paracrine viability factor for cutaneous T-cell lymphoma cells. Blood. 1998;92:252-8. (Pubitemid 28303200)
22. Qin JZ, Kamarashev J, Zhang CL, Dummer R, Burg G, Dobbeling U. Constitutive and interleukin-7- and interleukin-15-stimulated DNA binding of STAT and novel factors in cutaneous T cell lymphoma cells. J Invest Dermatol. 2001;117:583-9. (Pubitemid 32955584)
23. Qin JZ, Zhang CL, Kamarashev J, Dummer R, Burg G, Dobbeling U. Interleukin-7 and interleukin-15 regulate the expression of the bcl-2 and c-myb genes in cutaneous T-cell lymphoma cells. Blood. 2001;98:2778-83.
24. Van Doorn R, Dijkman R, Vermeer MH, Starink TM, Willemze R, Tensen CP. A novel splice variant of the Fas gene in patients with cutaneous T-cell lymphoma. Cancer Res. 2002;62:5389-92.
25. Li G, Chooback L, Wolfe JT, Rook AH, Felix CA, Lessin SR, et al. Overexpression of p53 protein in cutaneous T cell lymphoma: relationship to large cell transformation and disease progression. J Invest Dermatol. 1998;110:767-70. (Pubitemid 28194025)
26. Hwang ST, Janik JE, Jaffe ES, Wilson WH. Mycosis fungoides and Sezary syndrome. Lancet. 2008;371:945-57.
27. Center DM, Cruikshank WW. Modulation of lymphocyte migration by human lymphokines. I. Identification and characterization of chemoattractant activity for lymphocytes from mitogen-stimulated mononuclear cells. J Immunol. 1982;128:2563-8.
28. Cruikshank WW, Center DM. Modulation of lymphocyte migration by human lymphokines. II. Purification of a lymphotactic factor (LCF). J Immunol. 1982;128:2569-74. (Pubitemid 12124481)
29. Kurschner C, Yuzaki M. Neuronal interleukin-16 (NIL-16): a dual function PDZ domain protein. J Neurosci. 1999;19:7770-80. (Pubitemid 30225776)
30. Zhang Y, Kornfeld H, Cruikshank WW, Kim S, Reardon CC, Center DM. Nuclear translocation of the N-terminal prodomain of interleukin-16. J Biol Chem. 2001;276:1299-303. (Pubitemid 32096559)
31. Center DM, Cruikshank WW, Zhang Y. Nuclear pro-IL-16 regulation of T cell proliferation: p27(KIP1)-dependent G0/G1 arrest mediated by inhibition of Skp2 transcription. J Immunol. 2004;172:1654-60.
32. Nicoll J, Cruikshank WW, Brazer W, Liu Y, Center DM, Kornfeld H. Identification of domains in IL-16 critical for biological activity. J Immunol. 1999;163:1827-32. (Pubitemid 29382181)
33. Zhang Y, Center DM, Wu DM, Cruikshank WW, Yuan J, Andrews DW, et al. Processing and activation of pro-interleukin-16 by caspase-3. J Biol Chem. 1998;273:1144-9. (Pubitemid 28049215)
34. Cruikshank WW, Kornfeld H, Center DM. Interleukin-16. J Leukoc Biol. 2000;67:757-66.
35. Wilson KC, Cattel DJ, Wan Z, Rahangdale S, Ren F, Kornfeld H, et al. Regulation of nuclear prointerleukin-16 and p27(Kip1) in primary human T lymphocytes. Cell Immunol. 2005;237:17-27. (Pubitemid 41821078)
36. Wilson KC, Center DM, Cruikshank WW. The effect of interleukin-16 and its precursor on T lymphocyte activation and growth. Growth Factors. 2004;22:97-104. (Pubitemid 38923313)
37. Kornfeld H, Cruikshank WW, Pyle SW, Berman JS, Center DM. Lymphocyte activation by HIV-1 envelope glycoprotein. Nature. 1988;335:445-8.
38. Diaz-Griffero F, Qin XR, Hayashi F, Kigawa T, Finzi A, Sarnak Z, et al. A B-box 2 surface patch important for TRIM5alpha self-association, capsid binding avidity, and retrovirus restriction. J Virol. 2009;83:10737-51.
39. De Meester I, Korom S, Van Damme J, Scharpe S. CD26, let it cut or cut it down. Immunol Today. 1999;20:367-75. (Pubitemid 29356431)
40. Morimoto C, Schlossman F. The structure and function of CD26 in the T-cell immune response. Immunol Rev. 1998;161:55-70.
41. Luco RF, Maestro MA, Del Pozo N, Philbrick WM, De la Ossa PP, Ferrer J. A conditional model reveals that induction of hepatocyte nuclear factor-1alpha in Hnf1alpha-null mutant beta-cells can activate silenced genes postnatally, whereas overexpression is deleterious. Diabetes. 2006;55:2202-11. (Pubitemid 44743616)
42. Zhang Y, Tuzova M, Xiao ZX, Cruikshank WW, Center DM. Pro-IL-16 recruits histone deacetylase 3 to the Skp2 core promoter through interaction with transcription factor GABP. J Immunol. 2008;180:402-8.
43. Zhang C, Hazarika P, Ni X, Weidner DA, Duvic M. Induction of apoptosis by bexarotene in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action. Clin Cancer Res. 2002;8:1234-40. (Pubitemid 34517663)
44. Michel L, Dupuy A, Jean-Louis F, Sors A, Poupon J, Viguier M, et al. Arsenic trioxide induces apoptosis of cutaneous T cell lymphoma cells: evidence for a partially caspase-independent pathway and potentiation by ascorbic acid (vitamin C). J Invest Dermatol. 2003;121:881-93. (Pubitemid 37239135)
45. Nunez G, Benedict MA, Hu Y, Inohara N. Caspases: the proteases of the apoptotic pathway. Oncogene. 1998;17:3237-45. (Pubitemid 29043976)
46. Adachi H, Adams A, Hughes FM, Zhang J, Cidlowski JA, Jetten AM. Induction of apoptosis by the novel retinoid AHPN in human T-cell lymphoma cells involves caspase-dependent and independent pathways. Cell Death Differ. 1998;5:973-83. (Pubitemid 28510700)
47. Kaser A, Dunzendorfer S, Offner FA, Ryan T, Schwabegger A, Cruikshank WW, et al. A role for IL-16 in the cross-talk between dendritic cells and T cells. J Immunol. 1999;163:3232-8. (Pubitemid 29431824)
48. Edelson RL. Cutaneous T cell lymphoma: the helping hand of dendritic cells. Ann NY Acad Sci. 2001;941:1-11. (Pubitemid 32928328)
49. Lynch EA, Heijens CA, Horst NF, Center DM, Cruikshank WW. Cutting edge: IL-16/CD4 preferentially induces Th1 cell migration: requirement of CCR5. J Immunol. 2003;171:4965-8. (Pubitemid 37432773)